Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On January 18, 2022, Caleb DesRosiers, JD, MPA was appointed to the Board of
Directors. Mr. DesRosiers will serve on the Board until the next annual meeting
when he will be up for election to the Board by shareholders.
Mr. DesRosiers is currently a senior principal at Valuate Healthcare
Consultancy, a leading strategic and market access consulting firm, which is
part of Omnicom a multi-billion communication and consulting public company. He
focuses on pharmaceutical access, managed care, distribution, technology, and
M&A. Prior to joining Valuate, Caleb was the Chief Strategy Officer at
PrescribeWellness, LLC that transacted in 2019 to Tabula Rasa, a public company.
The Board has determined that Mr. DesRosiers meets the independence standards
adopted by the Board in compliance with the New York Stock Exchange corporate
governance listing standards and Item 407(a) of Regulation S-K.
Mr. DesRosiers has (i) no arrangements or understandings with any other person
pursuant to which he was appointed as a director, and (ii) no family
relationships with any director or executive officer of the Company or any
person nominated or chosen by the Company to become a director or executive
officer.
Mr. DesRosiers has had (i) no direct or indirect material interest in any
transaction or series of similar transactions contemplated by Item 404(a) of
Regulation S-K and, (ii) as of the date of this Current Report on Form 8-K, Mr.
DesRosiers holds no direct or indirect beneficial ownership in the Company's
stock or rights to acquire the Company's stock.
Mr. DesRosiers will receive the standard compensation, paid by the Company to
all of its non-employee directors and as described under "Board Compensation" in
the Proxy Statement. He has not yet been appointed to any committee of the
Board.
© Edgar Online, source Glimpses
DAXOR CORPORATION 
